AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve drug targeting problems and generate a new class of single domain antibody protein therapeutics with the potential to treat some of challenging medical conditions.
ASX Code | 1AD |
Website | http://www.adalta.com.au |
Industry/Sector | Biotechnology |
Market Cap ($M) | 14 |
1AD Share Price | $0.027 |
Day High | $0.028 |
Day Low | $0.027 |
Last Close | $0.027 |
1AD Share Price Movement | - ( No change ) |
There are no dividends for AdAlta Limited (1AD). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
SYNBV MoU Webinar presentation | 10 Apr 2024 8:46AM | $0.027 | $0.027 | $0.029 | fallen by 0% |
Webinar to discuss SYNthesis BioVentures partnership | 8 Apr 2024 9:03AM | $0.029 | $0.027 | $0.029 | fallen by 6.90% |
SYNThesis BioVentures MoU for cellular immunotherapies | 8 Apr 2024 8:57AM | $0.029 | $0.027 | $0.029 | fallen by 6.90% |
See all ASX announcements from AdAlta Limited (1AD) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2023A | -$4.85 | -$1.50 | -30.30% | 0.00 | 0.00 | 0.00% | 0.0% |
2022A | -$6.06 | -$2.20 | -8.40% | 0.00 | 0.00 | 0.00% | 0.0% |
2021A | -$5.63 | -$2.40 | -33.70% | 0.00 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
AdAlta (1AD) | $14M | -0.3028 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
CSL (CSL) | $132,750M | -0.0712 | 0.1072 | 0.1864 | 40.2043 | 36.3120 | 30.6072 | 1.30% | 1.22% | 1.37% |
Clinuvel Pharmaceuticals (CUV) | $759M | 0.4665 | 0.2049 | 0.1566 | 25.6345 | 21.2751 | 18.3949 | 0.33% | 0.46% | 0.53% |
Mesoblast (MSB) | $878M | -0.1037 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Telix Pharmaceuticals (TLX) | $4,207M | -1.3767 | 0.0000 | 0.0000 | 100.8716 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | 5.19 | 0.00 |
Market | 0.50 | 15.20 | 1.11 | 1.01 |
Sector | 1.26 | 21.30 | 1.90 | 0.97 |
Name | Position | Start Date |
---|---|---|
Dr Timothy Oldham | Managing Director, Chief Executive Officer | 8 Oct 2019 |
Dr Paul MacLeman | Non-Executive Chairman, Non-Executive Director | 16 Apr 2015 |
Dr David Fuller | Non-Executive Director | 22 Jul 2020 |
Dr Robert Peach | Non-Executive Director | 14 Nov 2016 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
19 Dec 2023 | OLDHAM, Timothy | Issued | Options | 5,600,000 | $0.013 | $70,694.000 |
19 Dec 2023 | FULLER, David | Issued | Options | 1,750,000 | $0.013 | $22,092.000 |
19 Dec 2023 | MACLEMAN, Paul | Issued | Options | 2,800,000 | $0.013 | $35,347.000 |
See all changes in directors' interest & trades for AdAlta Limited (1AD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Cameron Jones | Chief Financial Officer,Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in AdAlta Limited (1AD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
87,863,591 (19.90%) | Platinum Investment Management Limited |
53,594,168 (12.14%) | Meurs Holdings Pty Ltd |
27,029,924 (6.12%) | Fletcher Meurs Investments Pty Ltd |
Date | Event |
---|---|
25 February 2025 | Report (Interim) |
23 August 2024 | Report (Annual) |
23 August 2024 | Report (Prelim) |
AdAlta Limited's (1AD) current share price is $0.03. This constitutes a price movement of 6.90% when compared to the share price 7 days ago and is -18.18% below 1AD's 12-month high of $0.03 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.03, AdAlta Limited's (1AD) current share price of $0.03 constitutes a movement of or 0%. AdAlta Limited's (1AD) share price movement is -6.90% when compared to 7 days ago and is -18.18% below 1AD's 52-week high of $0.03.
AdAlta Limited's (1AD) 52-week high is $0.03 which was reached on 7 Jul 2023. Relative to this, 1AD's current share price of $0.03 constitutes a -$0.01 or -18.18% drop since that high of $0.03 per 1AD share.
AdAlta Limited's (1AD) 52-week low is $0.02 which was reached on 8 Sep 2023. Relative to this, 1AD's current share price of $0.03 constitutes a $0.01 or 58.82% gain since that low of $0.02 per 1AD share.
Over the last 12 months, AdAlta Limited (1AD) has a daily average trading volume of 974,480 1AD shares per day.
AdAlta Limited (1AD) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for 1AD is a ratio that tells you the percentage of AdAlta Limited's (1AD) share price that it pays out in dividends each year.
AdAlta Limited (1AD) will release its next Annual Report on 23 August 2024. AdAlta Limited's (1AD) last annual report was released on 25 Aug 2023. Click here to view AdAlta Limited's (1AD) last annual report.
AdAlta Limited (1AD) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for AdAlta Limited (1AD) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of AdAlta Limited's (1AD) share price to its earnings per 1AD share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.